We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Midatech Pharma Plc | LSE:MTPH | London | Ordinary Share | GB00BNGF1L75 | ORD GBP0.02 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 18.00 | 17.00 | 19.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
10/1/2019 15:14 | Rake - Looks like NOBBY is correct - Nobbygnome10 Jan '19 - 13:13 - 233 of 238 0 2 0 tomboy I think you are wrong in your comparison of prices. One ADS is equivalent to 2 shares on AIM so the price should be around 8p based on the US price. | tomboyb | |
10/1/2019 14:37 | Current price is 0.20c which equates to around 16 pence | rakepat37 | |
10/1/2019 14:27 | Lets see what the market over at U.S makes of the news today - Selling at 6.75p when the market across the pond is around 8pish mark - Will look to add further on any weakness - | tomboyb | |
10/1/2019 13:52 | Check out the 5 dollers price target | rakepat37 | |
10/1/2019 13:38 | yes I see now. thanks. | babbler | |
10/1/2019 13:19 | Nobby - Thanks - If u see my previous posts i was asking the question of that discrepancy - We are still below that share price (which is why i said i could not understand it and went in blindly at 6.25p) - | tomboyb | |
10/1/2019 13:13 | tomboy I think you are wrong in your comparison of prices. One ADS is equivalent to 2 shares on AIM so the price should be around 8p based on the US price. | nobbygnome | |
10/1/2019 12:36 | Check out @portefeuillefun's Tweet: https://twitter.com/ | aba978731dom | |
10/1/2019 12:34 | Back into ths 8p range here - Discrepancy is massive - It should certainly not be so - Which begs the question of MARKET MAKERS and arbitrage - | tomboyb | |
10/1/2019 12:33 | And now fully funded ... time to catch up to 16p | rakepat37 | |
10/1/2019 12:20 | convert it from dollars to GBP. What does the price equate to? Either a massive fall there or we need to catch up. | babbler | |
10/1/2019 12:14 | Look at the price it's worth 16p | rakepat37 | |
10/1/2019 12:07 | What am i missing here. When I look at the nasdaq chart it shows 16% rise not the 100% people are talking about.... | pilkersa | |
10/1/2019 12:03 | Well I bought on the shake. us open soon... | babbler | |
10/1/2019 11:30 | Idiotic punters are helping the MMs out by bailing out. Make their pips squeak! | nobbygnome | |
10/1/2019 10:49 | OT) Please look at Futura Medical (FUM) has a dirt low market cap of 22 Million and 3 Drugs including a potential MEGA Blockbuster in Phase 3 trial which is light years better than Viarga and Cialis . If you look for a potential 10+ Bagger then load up FUM Research Confirms MED2002's US$1 Billion Potential hxxps://futuramedica The latest market research further endorses Futura's strategy of developing MED2002 as a prescription product in standard and increased strength dose forms, with the objective of switching the standard dose form to an OTC product at an appropriate time. Ipsos's validated healthcare forecasting model was used to predict peak OTC annual sales for MED2002 in key countries worldwide in excess of US$650 million. This forecast follows earlier market research commissioned into the potential of MED2002 as a prescription product, which indicated a prescription market size of up to US$600 million in key countries worldwide. Ipsos forecasts that 70% of OTC product sales will be incremental to the prescription ED category. As a result, the estimated peak annual sales of MED2002 in prescription and OTC versions is predicted to be more than US$1 billion prior to the expiry of the product's expected patent life. The Ipsos valuation was based on the outcomes from primary market research carried out amongst 400 men with ED or suspected ED in the USA. The respondents were in four groups: satisfied users of PDE5 inhibitors (the class of drugs such as Viagra and Cialis); dissatisfied users of PDE5 inhibitors; diagnosed but untreated ED sufferers; and suspected though undiagnosed ED sufferers. The respondents were shown a concept about MED2002 as part of the market research though they did not use the product as it is currently in clinical development. The key findings of the market research showed that the respondents believed that the product, once approved, is highly differentiated from existing products and that its claims would meet their needs. MED2002's rapid onset of action, an average of less than five minutes, was the key feature that attracted respondents to the product and could command a price premium compared with existing ED treatments, which have a substantially slower onset of action. The Ipsos healthcare forecasting model has been demonstrated by Ipsos to be within 20% of actual sales volumes in 9 out of 10 of its forecasts. Pipeline hxxps://www.futurame MED2002 (topical treatment for erectile dysfunction) hxxps://futuramedica first patient dosed: in Q3/Q4 2018 Last patient dosed: by end of June 2019 Headline efficacy results: by end of December 2019 CSD500: Erectogenic condom hxxps://futuramedica Significant milestone achieved with approval of 2-year shelf life approved for CSD500, the erectogenic condom in September 2018. Development now complete. Discussions are ongoing with current and potential further distribution partners on next steps with the product in a number of markets. Pain relief products: TPR100 (diclofenac) and TIB200 (ibuprofen) hxxps://futuramedica TPR100 commercial partner Thornton & Ross filed for UK regulatory submission in July 2018. Out-licensing discussions for TPR100 outside of the UK are ongoing. | bioking | |
10/1/2019 10:49 | array of 6.25p buyers did well there..well done folks. | pre | |
10/1/2019 10:47 | Market makers in massive trouble here.... they desperately need some sellers but none appearing and unlikely to do so! | nobbygnome | |
10/1/2019 10:33 | Will be up 80-100% at this rate today - | tomboyb | |
10/1/2019 10:22 | Never seen that price discrepancy before and does not make sense - However i've taken a blind punt at 6.25p - | tomboyb | |
10/1/2019 10:22 | Can't believe people have not caught on that the USA market hit 16p last night -- wow this is going to go nuts | rakepat37 | |
10/1/2019 10:20 | Another 10p to go to get to 16p and then evens with USA, USA market opens soon then another uplift | rakepat37 | |
10/1/2019 10:03 | Correct me if i'm wrong but that looks like 15-16p? V 6.5p here - Views anyone? - | tomboyb | |
10/1/2019 10:02 | To me this looks like going 7p+ pretty soon - hxxp://www.midatechp NASDAQ value - | tomboyb | |
10/1/2019 09:42 | Took a few today - Any ideas why the huge discrepancy - ( Blind punt) | tomboyb |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions